The Patent Finder

Roskamp Research LLC

Also on record
Records under this name other than patents Roskamp Research LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Roskamp Research LLC

PatentTitleStatus Expires Confidence
US 7,732,467Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,067,372Modulation of angiogenesis by A-beta peptide fragments
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,236,346Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
Formerly held
Lapsed on the fee record
Ended Aug 7, 2024 · From the USPTO record
Lapsed on the fee recordEnded Aug 7, 2024From the USPTO record
US 8,236,347Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis
Formerly held
Lapsed on the fee record
Ended Aug 7, 2024 · From the USPTO record
Lapsed on the fee recordEnded Aug 7, 2024From the USPTO record
US 7,589,168Inhibition of Angiogenesis by A-Beta Peptides
Formerly held
Lapsed on the fee record
Ended Sep 15, 2021 · High confidence
Lapsed on the fee recordEnded Sep 15, 2021High confidence
US 6,011,019Vasoactive effects and free radical generation by .beta.-amyloid peptides
Formerly held
Term ended
Term ended Nov 12, 2016 · From the USPTO record
Term endedTerm ended Nov 12, 2016From the USPTO record
US 6,787,318Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
Formerly held
Lapsed on the fee record
Ended Sep 7, 2016 · From the USPTO record
Lapsed on the fee recordEnded Sep 7, 2016From the USPTO record
US 7,052,852CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
Formerly held
Lapsed on the fee record
Ended May 30, 2014 · From the USPTO record
Lapsed on the fee recordEnded May 30, 2014From the USPTO record
US 7,605,149Modulation of the phospholipase A2 pathway as a therapeutic
Formerly held
Lapsed on the fee record
Ended Oct 20, 2013 · From the USPTO record
Lapsed on the fee recordEnded Oct 20, 2013From the USPTO record
US 6,140,309Vasoactive effects and free radical generation by .beta.-amyloid peptides
Formerly held
Lapsed on the fee record
Ended Oct 31, 2012 · From the USPTO record
Lapsed on the fee recordEnded Oct 31, 2012From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited